All In Biotech

Drug Trial Radar · NCT03830333

Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)

A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infection

Last checked: Nov 20, 2026Latest source record: Jan 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 268 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

268

Actual

Start

Mar 20, 2019

Primary completion

Oct 14, 2020

Study completion Oct 14, 2020

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy of ceftolozane/tazobactam (MK-7625A) plus metronidazole versus meropenem in adults diagnosed with complicated intra-abdominal infection (cIAI). The primary hypothesis is ceftolozane/tazobactam plus metronidazole is non-inferior to meropenem, as measured by the clinical response rate at the Test-of Cure (TOC) visit in the Clinically Evaluable (CE) population.

Conditions

  • Complicated Intra-abdominal Infections

Interventions

  • Ceftolozane/TazobactamDrug

    Ceftolozane 1000 mg / tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive ceftolozane 500 mg / tazobactam 250 mg.

  • MetronidazoleDrug

    Metronidazole 500 mg by IV infusion every 8 hours for 4 to 14 days.

  • MeropenemDrug

    Meropenem 1000 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive IV infusion every 12 hours.

  • PlaceboDrug

    Saline by IV infusion every 8 hours for 4 to 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at Test of Cure (TOC) Visit: Clinically Evaluable (CE) PopulationTime frame: Up to approximately Day 30

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Southern Medical University Nanfang Hospital ( Site 0055)

    Guangzhou, China

  • Anhui Provincial Hospital ( Site 0033)

    Hefei, Anhui, China

  • Navy General Hospital ( Site 0009)

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital ( Site 0002)

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Guangzhou Medical University ( Site 0026)

    Guangzhou, Guangdong, China

  • Hainan General Hospital ( Site 0042)

    Haikou, Hainan, China

  • Baotou Central Hospital ( Site 0013)

    Baotou, Inner Mongolia, China

  • The First People's Hospital of Changzhou ( Site 0054)

    Changzhou, Jiangsu, China

  • Wuxi No.2 People's Hospital ( Site 0050)

    Wuxi, Jiangsu, China

  • Wuxi People's Hospital ( Site 0020)

    Wuxi, Jiangsu, China

  • Subei People's Hospital ( Site 0046)

    Yangzhou, Jiangsu, China

  • Affiliated Hospital of Jiangsu University ( Site 0049)

    Zhenjiang, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University ( Site 0029)

    Nanchang, Jiangxi, China

  • The Second Affiliated Hospital of Nanchang University ( Site 0053)

    Nanchang, Jiangxi, China

  • The Second Hospital of Jilin University ( Site 0048)

    Changchun, Jilin, China

  • Liaocheng People s hospital ( Site 0014)

    Liaocheng, Shandong, China

  • Zhongshan Hospital of Fudan University ( Site 0001)

    Shanghai, Shanghai Municipality, China

  • Shanghai General Hospital ( Site 0016)

    Shanghai, Shanghai Municipality, China

  • Central Hospital of Minhang District ( Site 0052)

    Shanghai, Shanghai Municipality, China

  • Tianjin People's Hospital ( Site 0040)

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital of Xinjiang Medical University ( Site 0034)

    Ürümqi, Xinjiang, China

  • The First Hospital of Kunming ( Site 0041)

    Kunming, Yunnan, China

  • Taizhou Hospital of Zhejiang Province ( Site 0035)

    Taizhou, Zhejiang, China

  • The 2nd Affiliated Hospital of Wenzhou Medical University ( Site 0051)

    Wenzhou, Zhejiang, China

  • The First Affiliated Hospital of Wenzhou Medical University ( Site 0015)

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.